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Case presentation
A 65-year-old white man was referred to The University Hospital for
management of complications of the nephrotic syndrome. He had gone
to a private physician 3 months carlier complaining of scveral months of
ankle swelling; he was found at that time to have nephrotic syndrome.
The 24-hour urinary protein excretion was 18.2 g, and a renal biopsy
showed membranous nephropathy. The plasma creatinine was 1.5
mg/dl; the BUN, 20 mg/dl; and the calculated creatinine clearance, 110
mI/mm. An extensive search failed to disclose a secondary cause for the
glomerular lesion. Renal ultrasound examination revealed normal-sized
kidneys, and a renal venogram demonstrated patent renal veins. Treat-
ment was started with prednisone, 120 mg every other day, together
with furosemide. Two months later he still had severe edema. Urinary
protein excretion was 12 g/24 hr and the serum creatinine had increased
to 1.9 mg/dl. The serum albumin was 2.0 g/dl and total protein was 5
gAll. The hematocrit was 35%, and the white blood cell count was 7500
cells/mm3. The prednisone dose was reduced to 100 mg every othcr
day. A low-salt diet was instituted, and metolazouc was added to the
diuretic regimen. He was examined 2 weeks later because of persistent
edema and a 3-day history of productive cough with fever and chills. He
had no chest pain or hemoptysis. He had not lost any weight since his
last visit. He was transferred to The University Hospital for continuing
management.
Physical examination revealed an ill-looking white man who was
taehypoeic and pale but mentally alert. He was 20 kg above his usual
weight, and 4± edema of the legs was present. Respiratory rate was
30/mm; the pulse was 100 beats/mm and regular. All pulses were
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present and equal. The temperature was 100°F. The blood pressure was
110/70 mm Hg in the right arm with the patient supine and standing. The
patient had no skin rashes, peteehiae, clubbing, or jaundice. Examina-
tion of the head and neck revealed intact cranial nerves and normal
fundi. Ears, nose, and throat were normal. The jugular venous pressure
was not increased. No lymph glands were palpable in the neck or
axillae, and the trachea was midline, cardiac examination was normal.
Examination of the lungs revealed coarse rales at the right base but no
other abnormalities. Abdominal examination revealed aseites, but no
abdominal guarding, tenderness, or rigidity. The liver and spleen were
not palpable and no masses were present. The urine contained 4±
protein; microscopic examination revealed free fat droplets, many oval
fat bodies, and numerous fatty casts. Five to 10 red blood cells were
seen per high-power field, but no red blood cell casts were present. A
24-hr urine collection contained 8 g of protein.
The BUN was 22 mg/dl; creatinine, 2.0 mg/dl; and electrolytes were
normal. Serum total calcium was 7.8 mg/dl, and the phosphorus was 4.0
mg/dl. Hematocrit was 35% and the white blood cell count 15,000
cells/mm3. The erythroeyte sedimentation rate was 82 mm in the first
hour. Total protein was 4.3 g/dl; albumin, 1.3 g/dl; alpha-I globulin, 0.2
g/dl (normal, 0.15—0.40 gAll); alpha-2 globulin, 1.41 g/dl (normal,
0.40—0.90 g/dl); beta globulin, 0.96 g/dl (normal, 0.50—1.10 gAll); and
gamma globulin, 0.42 g/dl (normal, 0.60—1.60 g/dl). The tgG was 596
mg/dl (normal, 750—1650 mg/dl); IgA, 70 mg/dl (normal. 80—390 mg/dl);
and 1gM, 160 mg/dl (normal, 60—270 mg/dl). Total cholesterol was 420
mg/dl (normal, 150—280 mg/dl) and triglyceride 364 mg/dl (normal,
40—20(1 mg/dl). The HDL cholesterol was 22 mg/dl (normal, 30—70 mg/dl)
and the LDL cholesterol 109 mg/dl (normal, 62—185 mg/dl). chest x-ray
revealed an interstitial infiltrate at the right base and bilateral pleural
cffusioos.
Antibiotic treatment was initiated and diuretics and a low-salt diet
were continued. Prednisone was tapered. l'he pneumonia cleared up
rapidly, but increasing doses of diuretics, and eventually salt-poor
albumin infusions, were needed to promote a diuresis; the edema,
however, did not resolve. Further investigation revealed a 25 hydroxy-
vitamin D level of 4 ng/ml (normal, 10—15 ng/ml) with a 1,25 dihydroxy-
vitamin D level of 33 pg/mI (normal, 20—76 pg/mI). The PTH (C-
terminal) was 227 pg/mI (normal, up to 340 pg/nil). Plasma zinc was 36
,ag/dl (normal, 60—130 jig/dO; transferdn, 135 mg/dl (normal, 200—400
mg/dI); and serum iron was normal (101 jig/dI). The patient was
discharged after 2 weeks for followup in renal clinic.
Discussion
DR. DAVtD H. BERNARD (Director, Clinical Renal Unit, The
Uttis'ersity Hospital, and Associate Profrssor of' Medicine,
Evans Memorial Department of Clinical Research and Depart—
,'nent of' Medicine, Boston University Sc/tool o,f Medicine,
Boston, Massachusetts): The case under discussion aptly dem-
ons(rates an important aspect of severe nephrotic syndrome,
namely i(s association with many extrarenal metabolic compli-
cations. These complications account for much of the morbidity
of the disease, and some are so serious that they threaten the
life of the patient, even when renal function is normal. Compli-
cations arc frequently detectable, at least initially, by biochem-
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Fig. 2. Daily albumin turnover in normal
individuals and patients with nephrotic
syndrome. Values for albumin filtration by
the glomerulus are derived from animal
studies. Note that in nephrotic syndrome
the rates of albumin synthesis and absolute
catabolism are normal or are increased
slightly. Yet each day a greater-than-
normal fraction of intravascular albumin is
catabolized. Albumin catabolism by renal
tubular epithelium is increased; it is
presumed that a portion of filtered albumin
is returned to the body pool. From Ref. I
by permission.
ical testing rather than by clinical examination, are usually
ignored in discussions of treatment and prognosis, and repre-
sent an area of much controversy [11. Figure 1 represents the
many metabolic manifestations of nephrotic syndrome. The
figure illustrates that the common pathophysiologic defect that
initiates these varied manifestations is an increased glomerular
permeability to plasma proteins, and that the proximate cause
of the major derangements is hypoalbuminemia.
Patho genesis of hypoalbuminemia in nephrotic syndrome
Most patients with nephrotic syndrome, like the patient we
are discussing today, develop hypoalbuminemia at some stage
during the course of their disease. In general, the greater the
magnitude of the proteinuria, the lower the serum albumin
concentration. A convenient way of exploring the mechanism
of hypoalbuminemia in nephrotic syndrome is to compare
albumin metabolism in the normal individual and in the patient
with nephrotic syndrome (Fig. 2). In the normal person, albu-
min production by the liver is 12—14 g/day (130—200 mg/kg);
production equals the amount catabolized, predominantly in
extrarenal locations [2]. A small amount, about 10%, is catab-
olized in the kidney, presumably by tubular reabsorption of
filtered albumin.
How is this state altered in nephrotic syndrome? Hypoalbu-
minemia can result from a decreased rate of albumin synthesis,
an increased rate of albumin catabolism, changes in albumin
distribution, decreased intake of dietary protein, or loss of
albumin from the body. In nephrotic syndrome, several of these
factors appear to be at work. Clearly, the loss of albumin in the
urine is important. However, protein loss is by itself an inade-
quate explanation for hypoalbuminemia in most patients with
nephrotic syndrome because the rate of hepatic albumin syn-
thesis normally can increase by at least threefold and should
easily be able to compensate for the usual urine losses [2].
Studies in humans and in animal models of nephrotic syndrome
demonstrate that the rate of albumin synthesis is at the upper
limit of normal or slightly above normal as long as dietary
protein is adequate [3, 4]. In patients on low-protein diets,
however, synthesis rates can be below normal [4]. Studies using
turnover techniques [5], liver perfusion methods [6], isolated
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Fig. 3. Filtration and absorption of albumin.
Values for amounts filtered and excreted are
given in p.g/min as corrected for 100 g body
weight. Albumin absorption is listed as
absolute amount (arrows and numbers right of
tubules) and as percentage of filtered load
(arrows and numbers left of tubules). From
Ref. 19. 5Refers to animals with prolonged
proximal transit times anti reduced GFRs.
liver mierosomal preparations [7], and measurements of albu-
min messenger RNA [8] give evidence of increased hepatic
albumin synthesis. Interestingly, the rate of hepatic albumin
synthesis seems not to be related to plasma albumin concentra-
tions, but to a reduction in extravascular pools of albumin,
perhaps even within the liver itself [9]. Although hepatic
albumin synthesis is not low in absolute terms, it is low relative
to the serum albumin level. A good analogy is the patient
undergoing continuous ambulatory peritoneal dialysis (CAPD):
daily extrarenal albumin losses from the peritoneum in such
patients are similar to urinary protein losses in nephrotic
syndrome [101. Yet in patients undergoing CAPD, hepatic
albumin synthesis increases gram for gram to compensate for
losses, and the serum albumin concentration typically remains
normal or is only slightly reduced 1111. Thus, the liver's
response in nephrotic syndrome to renal albumin losses clearly
is inadequate; presumably. if hepatic synthesis were increased
towards nearly maximum levels, plasma albumin might be
restored to normal. The fact that this does not happen might be
due to some kind of nutritional deficiency, because feeding a
high-protein diet to patients with nephrotic syndrome increases
hepatic albumin synthesis [4] and may even restore serum
albumin levels towards normal [12].
The rate of albumin catabolism in nephrotic syndrome also
has been examined. Although absolute catabolic rates fre-
quently are normal [3, 131, the rate of fractional catabolism
often is increased, particularly if protein intake is poor 13, 141.
As Figure 2 illustrates, 5% to 12% of the intravascular albumin
pool is catabolized in the normal person each day. In many
patients with nephrotic syndrome, this fraction is in the range of
16% to 50%, The major site of increased catabolism appears to
be the kidney, the catabolism presumably resulting from tubular
uptake and breakdown of filtered albumin. Several studies both
in humans and animals demonstrate that albumin catabolic rates
increase as proteinuria increases; these findings suggest more
tubular uptake and catabolism as the nephrotie state worsens
[3, 14]. If rats with experimental nephrotic syndrome are
nephrcctomized, albumin catabolism decreases by 50% [5];
morphologically, protein absorption droplets containing both
albumin and globulin have been demonstrated in proximal and
distal cells of rats with experimental nephrotic syndrome [15];
lysozymal activity (cathepsin B and L) in tubular cells is
increased in response to glomerular proteinuria [16].
The contribution of renal albumin catabolism to hypoalbu-
minemia in nephrotic syndrome is controversial, Some have
argued that the renal tubular albumin transport mechanism is at
virtual saturation at physiologic levels of filtered albumin and
that any increase in filtered protein cannot be absorbed and
cataholized, hut is simply excreted in the urine [171. In a recent
study of isolated perfused proximal tubules, however, Park and
Maack demonstrated a dual transport system for albumin
uptake [181. Although a low-capacity system was present that
did become saturated when the protein load exceeded physio-
logic levels, a high capacity-low affinity system also was present
that permitted tubular absorptive rates for albumin to increase
as the filtered load rose. Furthermore, data from a micropunc-
ture study of nephrotoxic nephritis (Fig. 3) show that although
absolute tubular absorptive rates for albumin were not in-
creased in many animals, absorption was 10 times greater than
control in about 50% of the animals. Extrapolation to humans of
the data on the albumin sieving coefficients of glomeruli from
nephrotic rats suggest that 10 to 60 g of albumin could be filtered
each day in human nephrotic syndrome [191. One clearance
study in humans with nephrotic syndrome concluded that the
level of filtered albumin was about 25 to 60 g/day, a finding in
close agreement with the calculations derived from rat studies
[201. If these figures are even close to being correct, the kidney
probably is an important site of albumin catabolism, because
the daily urine protein excretion in patients with nephrotic
syndrome usually is much less than this amount. Although
some of the constituent amino acids of the absorbed and locally
metabolized albumin may be returned to the circulation to he
re-used, some may be catabolized within the renal tubules and
lost from the total-body protein pool. Loss of albumin froni the
gastrointestinal tract has been shown to occur in some studies
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[211 but not others [221 and seems unlikely to be a major factor
in the pathogenesis of hypoalbuminemia.
Figure 2 displays a model of albumin metabolism in nephrotic
syndrome. Hypoalbuminemia occurs because of increased loss
of albumin in the urine and, in some instances, because of an
increased rate of albumin degradation by the kidney. Such
losses occur in conjunction with a rate of hepatic synthesis that,
although not reduced in absolute terms, is not increased enough
to maintain the plasma level. When proteinuria is modest, the
catabolic rate of albumin is not markedly increased, the rate of
albumin synthesis is nearly normal, and hypoalbuminemia then
may be caused by urine protein losses and inadequately in-
creased synthesis. At higher rates of albuminuria, however,
albumin catabolism increases as large amounts of filtered albu-
min are absorbed and degraded by the tubules. Under these
circumstances, protein loss and protein catabolism both con-
tribute importantly to the pathogenesis of hypoalbuminemia. In
the most severe cases, absolute albumin turnover rates can
exceed 50% of the intravascular pool per day. The influence of
dietary protein intake on plasma albumin concentration is an
important issue that requires further study. In one recent study
[12], despite massive proteinuria, plasma albumin concentra-
tions were in a nearly normal range (> 3 g/dl). The authors
report this to be their usual experience because they always
offer '. . . appropriate protein and calorie supplementa-
tion to their patients. On the other hand, other studies
have demonstrated that catabolic and excretion rates increase
pan passu with high protein intake and that the final serum
albumin concentration is unaffected or even slightly lower [4,
13]. For the moment it seems advisable for us to encourage
high-protein diets (1.5—2.0 g/kg/day in adults; up to 5.0 g/kg/day
in growing children) in nephrotic subjects with very low plasma
albumin concentrations (below 2.0—2.2 g/dl).
Consequences of hypoalbuminemia
Hypoalbuminemia has many deleterious effects. Although
blood volume is normal in most cases, patients with nephrotic
syndrome are remarkably sensitive to any further losses of
blood volume. Shock and pre-renal azotemia can occur follow-
ing minimal losses of fluid during minor surgical procedures,
with the use of diuretics, or even spontaneously [23]. Several
instances of acute renal failure have occurred, probably as a
result of prolonged or critical hypoperfusion [24]. Severe renal
failure also has been described in the absence of impressive
tubular or interstitial changes on renal biopsy; this complication
has been attributed either to hemodynamic factors or to edema
of the renal interstitium [25, 26]. Patients with nephrotic syn-
drome also are prone to develop acute renal failure from
nonsteroidal antiinflammatory drugs. The fall in glomerular
filtration rate induced by these agents usually is reversible [27,
281, but that is not always the case [29]. In fact, these agents
have been used to cause permanent renal failure (a "medical
nephrectomy"), when obliteration of renal function in severe
nephrotic syndrome is necessary to prevent life-threatening
metabolic complications [301. Some studies have suggested that
the agent sulindac is less likely to be as harmful in this regard
[28].
Hypoalbuminemia also has an important pharmacologic con-
sequence, namely the potential for enhanced drug toxicity
because of a reduced availability of drug binding sites [31].
Because many drugs carried in the blood are bound to albumin,
hypoalbuminemia can result in higher circulating levels of free
drug when usual doses of the drug are administered. The high
incidence of toxic reactions with clofibrate in patients with
nephrotic syndrome is an example of reduced drug binding in
hypoalbuminemic plasma. Such complications are avoidable if
the drug is given at a dosage of about one-half the usual dose
[32]. The use of warfarin, a drug tightly bound to albumin, also
requires close monitoring because of unpredictable effects on
coagulation factors [33]. Hypoalbuminemia also might play a
role in the platelet hyperaggregability in nephrotic syndrome
[34]. Because albumin normally binds arachidonic acid, thus
limiting its conversion to thromboxane A, by platelets, hypoal-
buminemia might allow increased platelet arachidonic acid
metabolism to take place, and platelet hyperactivity may result
[34]. Hypoalbuminemia also plays a key role in the pathogene-
sis of nephrotic hyperlipoproteinemia and edema.
Edema formation
As in the patient under discussion, swelling of the lower limbs
or weight gain frequently is the reason the patient with ne-
phrotic syndrome seeks medical advice. Indeed, edema, the
clinical expression of an expanded extracellular fluid compart-
ment, is present in almost all patients at some time during the
course of the disease. The fact that hypoalbuminemia plays
some role in edema formation in nephrotic syndrome is sug-
gested by the usual appearance of edema after the plasma
albumin concentration falls below 2.5 g/dl. For progressive
extracellular fluid expansion to develop, the kidneys must
concomitantly retain salt and water; the pathophysiology of this
renal avidity requires explanation as we consider the mecha-
nisms of edema formation.
According to the traditional view, lowering of the plasma
albumin concentration is the initiating step in renal sodium
retention [35]. Hypoalbuminemia results in a reduction in the
colloid oncotic pressure of the blood, favoring movement of
water from intravascular to interstitial space and producing
hypovolemia. Hypovolemia then activates volume sensors and
baroreceptors which, via a variety of intrarenal and extrarenal
neurohumoral and hemodynamic mechanisms, signal the kid-
ney to retain salt and water [35]. In this way, sodium retention
is viewed as the expected and physiologically appropriate
response by the kidney to the reduced circulatory volume, and
it protects the organism from progressive contraction of plasma
volume.
For unequivocal confirmation of this hypothesis, the follow-
ing must be true: blood and plasma volumes must be reduced
during the accumulation of edema; maneuvers that increase
plasma volume into the normal range in edematous patients
with nephrotic syndrome must induce a natriuretic response;
and functional evidence of hypovolemia can be demonstrated,
such as circulatory and humoral changes. In recent years,
several studies have failed to confirm these critical predictions,
and the classic theory, albeit logical and convenient, has been
brought into question. Furthermore, in many instances of
severe hypoalbuminemia in experimental animals and humans,
edema is not present [36, 37]. This observation suggests not
only that renal sodium retention in nephrotic syndrome might
be occurring via some other mechanism, but also that an
edema-preventing mechanism must be present to obviate
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edema despite hypoalbuminemia [36, 37]. Indeed, an alternate
hypothesis has been advanced to explain sodium retention,
namely, that renal sodium retention is primary and is the
consequence of intrarenal rather than systemic factors [38—4l].
The major reason for concluding that a primary reduction in
renal sodium excretion might he a better explanation for sodium
avidity in nephrotic syndrome is the lack of consistent reduc-
tions in blood and plasma volumes in patients with nephrotie
syndrome. In one analysis ol' more than 250 patients with
nephrotic syndrome, measured blood volume was reduced in
only 30% and was normal or increased in the rest [39]. Recent
studies have found low blood volumes to he even less common
[4l—45]. Furthermore, when blood and plasma volumes were
measured in the edematous patients again after they had
undergone remission and lost their edema, intravascular vol-
ume frequently was unchanged or even lower after edema
resolved [39, 46]. Some have suggested that two groups of
nephrotie patients exist, separable according to their blood
volume levels: those with low blood volumes, generally repre-
sented by patients who have minimal-change disease with
normal renal function, and those who have normal or elevated
blood volumes, generally represented by patients who have
both reduced renal function and structural renal disease [471.
Others have not found it possible to consistently separate their
patients in this way [39, 41, 43]. In summary then, it is fairly
well accepted now that the majority of patients with nephrotic
syndrome have blood and plasma volumes that are normal or
high, a finding in clear conflict with traditional concepts of
edema formation in this disorder.
'l'he conclusion that hypovolemia usually is not present and
thus not the stimulus to renal sodium retention in nephrotic
syndronie is confirmed by the variable natriuresis noted in
response to volume expansion. Despite substantial volume
expansion produced by hyperoncotic plasma infusion, an ade-
quate diuresis and natriuresis occurs in only about one-half of
patients 1481. In one study, patients with nephrotic syndrome
and edema were given 41) g of salt-poor albumin each day for 3
consecutive days. Whereas plasma volumes were shown to
have increased into a normal or above-normal range in all
patients, urine sodium excretion remained below daily intake,
and all patients gained weight [49]. The renal effects of neck-out
immersion in a water bath for several hours, a well-established
method of inducing central volume expansion, also have been
examined in patients with nephrotie syndrome [50, 51]. An
increase in urinary sodium excretion occurs in all patients,
although individual responses vary widely. In one study, de-
spite the existence ol' normal or high blood volumes before
immersion in 7 of 8 subjects, peak response in sodium excretion
varied from 55 to 488 zEq/niin [50]. These data suggest that
volume expansion alone is unable to overcome antinatriuretic
inlluenees in all cases and that other factors are involved.
Another interesting observation in the water-immersion studies
is that whereas free-water clearance increased markedly in the
first 2 hours, sodium excretion increased later. 'l'his suggests
that volume expansion during the early immersion period led to
increased delivery of fluid to the distal nephron hut that distal
sodium chloride reabsorption had remained high, thus generat-
ing increased free water, Only towards the end of the immersion
period, when volume expansion presumably had been present
for several hours, did the urinary sodium excretion peak,
favoring the notion that some stimulus apart from hypovolemia
had been responsible for renal sodium avidity [50, 511.
Finally, functional evidence of hypovolemia also cannot he
demonstrated consistently in nephrotie syndrome. For exam-
ple. plasma renin activity and aldosterone concentrations or
excretion rates in patients with nephrotic syndrome are vari-
able: plasma renin activity and plasma aldosterone concentra-
tions or excretion rates are high in fewer than 50% of the eases
[39, 41, 431. Also, no close correlation exists between changes
in plasma renin activity or aldosterone and blood volume [39,
41]. Other humoral markers of hypovolemia, such as norepi-
nephrine and vasopressin levels, also are normal in nephrotic
syndrome [43]. At a clinical level, changes in blood pressure in
nephrotie patients during relapse and remission also argue
against significant hypovolemia. Many patients have elevated
pressures during relapse that return to normal following reniis-
sion [39, 41. 52].
Taken together, these data suggest that the commonly held
view that hypovolemia in nephrotie syndrome is responsible for
renal sodium retention and edema cannot he supported in many
eases. If renal retention of sodium is the primary initiating
factor, blood volume would become expanded, and this de-
rangement would elevate blood pressure and suppress plasma
renin activity and aldosterone levels. Edema would develop by
"overflow"; that is. the expanded plasma volunie would leak
into the interstitiuni under the influence of altered local Starling
l'orees.
Although this scenario has considerable experimental sup-
port, pathophysiologie mechanisms in some patients with ne-
phrotie syndrome and edema still can be fitted more conve-
niently into the traditional view. I believe that no single
mechanism can he invoked to explain all eases of renal sodium
retention in nephrotic patients. Perhaps different mechanisms
are operative in different patients, or several mechanisms might
be at play in any one patient at different times, depending on
factors such as the specific underlying glomerular lesion, the
stage of evolution of the sodium retentive process. dietary salt
intake, the posture of the patient, the presence and severity of
associated heart or liver disease, and a host of additional
factors.
Two studies of puromycin aminonueleoside (PAN)-indueed
nephrotie syndrome have produced direct evidence of renal
sodium retention from one or more local intrarenal causes 153,
54]. In each study, one kidney of each animal was perfused with
PAN and the other not, so that unilateral proteinuria was
produced and hypoalbuminemia did not develop. Most interest-
ingly. sodium excretion was normal or high from the non-
perfused, control kidneys, but was reduced significantly in the
PAN-pert'used. proteinurie kidneys. Proteinuria occurred when
plasma protein concentration, and presumably blood volume,
was normal, and when systemic factors that might stimulate
secondary renal sodium retention should have been absent.
'Thus the renal sodium retention seems to have been a primary
phenomenon due to intrarenal influences. These elegant studies
offer the first strong evidence for the presence of an intrarenal
factor or factors that promote sodium retention by proteinurie
kidneys. A recent study in which a small group of patients with
minimal-change disease was studied before, during, and after
the onset of steroid-induced remission lends support to the
notion of a primary intrarenal defect in sodium excretion [41].
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At the time of remission, defined as the day on which urine
sodium excretion approximated sodium intake, no changes
were noted in plasma albumin concentration (which was low) or
blood volume (which was normal); further, blood pressure fell.
An intrarenal defect in sodium excretion that was removed at
the initiation of the natriuresis seems the best explanation for
these observations [41]. The intrarenal factors responsible for
sodium retention could relate to a reduction in glomerular
filtration rate or to increased tubular reabsorption. For exam-
ple, one recent study concluded that changes in glomerular
filtration were most important [43], whereas others have re-
ported defects in the atrial release of [55] or renal response to
[561 atrial natriuretic peptide. On the other hand, in a recent
report of children with nephrotic syndrome in relapse, plasma
levels of atrial natriuretic peptide were considered to be normal
and to rise appropriately in response to hyperoncotic albumin
infusion [57]. Further elaboration of the potential mechanisms
is needed. In the meantime, a new diagram summarizing current
concepts of the events leading to edema formation in nephrotic
syndrome must be developed, and I oiler one in Figure 4.
When it became clear that blood and plasma volumes were
usually normal in patients with nephrotic syndrome, several
investigators began to explore the mechanisms responsible for
the maintenance of euvolemia in the presence of hypoalbumin-
emia. The normal levels were a surprising finding, given tradi-
tional concepts of the factors controlling fluid movement from
intravascular to interstitial compartments. Using a technique
described in the 1970s [58], careful studies of interstitial tissue
colloid osmotic pressures (COP) were carried out in normal
individuals and in patients with nephrotic syndrome during
relapse and remission [44, 45, 59, 60]. In normal humans,
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Fig. 5. Relations/zip betzz'eenplasma and tissue—fluid oncorim pressure
(COP) in /2 patients zit/t the nep/trotic syndrome, at the first visit (0)
and during the j/1owup ofó patients with partial or complete recoz'erv(•i. Dashed line refers to the line of identity. From Ref. 59.
plasma COP is about 24 mm Hg (range, 22—25 mm Hg), and
interstitial COP is about 12 mm Hg (range, 10—13 mm Hg),
creating a transcapillary COP gradient of approximately 12 mm
Hg [45. 59, 60]. In nephrotic syndrome, the COP of interstitial
fluid falls virtually in parallel with the COP of the plasma as
hypoalbuminemia develops. Thus, the net transcapillary COP
gradient is maintained in the normal range, and any anticipated
driving force for fluid movement out of the intravascular space
is dissipated. Studies of the same patients during relapse and
remission showed almost equivalent changes in the COP of
interstitium and plasma (Fig. 5) at all levels of serum albumin
[59]. This virtually constant transcapillary difference in oncotic
pressure, maintained despite considerable reductions in plasma
albumin concentration, permits blood volume to be maintained
and edema formation to be avoided, as long as the plasma COP
is greater than 10—12 mm Hg. When COP falls below this level
(usually reflected by a plasma albumin of under 2 g/dl). this
compensatory mechanism no longer works, the transcapillary
COP gradient falls, and fluid moves into and accumulates in the
interstitial space. In one study, edema of the legs was noted
when the plasma COP dropped below 16,5 mm Hg, whereas
generalized edema occurred only when COP fell below II mm
Hg [60]. The reduction in interstitial COP is thought to arise by
acceleration of lymphatic flow, which returns interstitial protein
to the vascular compartment [45, 59]. It is assumed that this
phenomenon, called "protein washout." is triggered by a slight
rise in interstitial volume and hydrostatic pressure induced by
the initial transudation of fluid out of the circulation. Body
albumin pools are redistributed so that a greater fraction than
normal is located in the vascular compartment; blood volume is
maintained and edema is prevented.
A further aspect of this edema-preventing and blood-volume-
maintaining mechanism is the relationship that arises between
blood volume and extracellular fluid changes as fluid retention
occurs, In normoalbuminemic patients retaining fluid because
of renal failure, blood volume rises steadily as extracellular fluid
volume increases by the time extracellular fluid volume has
increased by 30%, blood volume has increased by the same
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Fig. 4. New concepts of the pathophzvsiologv of edema formation in
nephrorie syndrome.
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percentage [42]. Above this level of extracellular fluid expan-
sion, blood volume increases no further. In patients with
nephrotic syndrome and hypoalbuminemia, blood volume in-
creases much less, by under 10%, with evet, greater increases in
extracellular fluid volume: the curve relating extracellular fluid
volume and blood volume is almost flat at all levels of extracel-
lular fluid [42, 52]. Thus the blood volume is substantially
increased in overhydrated norinoalbuminemic patients but is
maintained in the normal range in nephrotic patients whether
hydration is increased or not. Some have considered this
homeostatic mechanism an important one that protects against
significant intravascular volume expansion and hence also
protects against severe hypertension, so common in compara-
bly fluid-expanded patients with renal failure. This difference
probably can be explained by the protein-washout phenome-
non. In normoalbuminemic patients with renal failure, protein
washout begins with the initial increase in extracellular fluid
volume; the increased fluid thus is retained initially in the
circulation. In patients with nephrotic syndrome, protein wash-
out already has occurred, even prior to significant body fluid
expansion; as extracellular fluid increases with renal fluid
retention, most of the retained fluid immediately translocates
into the interstitium, and the blood volume does not increase
further. In the patients with the lowest plasma albumin concen-
trations, in whom a transcapillary COP gradient cannot be
maintained, blood volume actually can be below normal. This
unusual state is likely to occur only when the plasma albumin
falls below 1.5 gldl; in such instances fluid retention may not
restore blood volume to normal.
These new observations have important implications for the
treatment of edema in nephrotic syndrome. Previously it had
been assumed that edema was a prerequisite for maintaining a
normal blood volume in nephrotic subjects, but that seems not
to be the case, Blood volumes are normal even in the absence
of edema in these patients [42, 44, 521. Interestingly, when
edema is eliminated with diuretics, but hypoalbuminemia per-
sists, the tissue fluid COP remains low and the blood-volume-
maintaining mechanism is preserved [44]. In most cases, edema
can be resolved quite safely in nephrotic subjects, and often
quite vigorously, without endangering the circulation. In one
report, a mean removal of 7.4 liters of fluid by ultrafiltration
over 2 days, which reduced the interstitial volume by 20%,
produced no changes in blood volume or creatinine clearance
[61]; in another study, the removal via diuretic therapy of more
than 13 liters of fluid from edematous nephrotic patients re-
sulted in their becoming free of edema while maintaining normal
blood volume [441. Plasma refilling from interstitial fluid follow-
ing diuresis seems to occur quite rapidly, although it slows
down as hydration becomes normal. The rate of weight loss
thus should be reduced as edema diminishes, and the patient
should be monitored carefully for evidence of postural hypo-
tension.
Pathophysiology of hyperlipidemia and hyperlipoproteinemia
As in the patient under discussion today, virtually all blood
lipid and lipoprotein fractions are elevated in nephrotic syn-
drome [1]. Blood levels of total serum cholesterol and phospho-
lipids almost always are increased and continue to rise as the
severity of nephrotic syndrome worsens [621. Total cholesterol,
free cholesterol, and cholesterol esters all are increased [63].
Fig. 6. Normal unidirectional metabolic pathway of lipoproteins.
Defects at sites I to 6 result in hyperlipoproteinemia. HDL = high-
density lipoprotein; LCAT lecithin-cholesterol acyltransferase;
VLDL very-low-density lipoprotein; LPL lipoprotein lipase;
APO-Cli = apolipoprotein C-Il; IDL = intermediate-density lipopro-
tein; LDL = low-density lipoprotein; CE =- cholesterol ester; TG =
triglyceride. From Ref. I by permission.
Levels of triglyceride are more variable and in many patients do
not increase at all, except when the nephrotic state is very
severe [62, 64]. Plasma levels of free fatty acids are within
normal limits in nephrotic syndrome, although a smaller-than-
normal fraction is bound to plasma albumin [62]. The very-low
density (VLDL), intermediate-density (IDL), and low-density
(LDL) lipoproteins also increase early in nephrotic syndrome
[62—67]; the data on high-density lipoproteins (HDL) are less
clear. Abnormalities in the composition of the lipoprotein
molecule also are present in nephrotic syndrome. Greater-than-
usual amounts of cholesterol and triglyceride are present in
VLDL, IDL, and LDL, and an alteration in the specific type
and quantity of the various apoprotein moieties of the lipopro-
tein molecule also has been described [I, 671. Finally, the
plasma level of certain apolipoproteins is also increased [68,
69]. These abnormalities return to normal fairly promptly when
the syndrome remits [I].
Plasma lipids as well as lipoproteins can be increased because
of an increased rate of synthesis, a decreased rate of removal,
increased mobilization from fat stores, or combinations of these
factors, Figure 6 illustrates the normal pathway of lipoprotein
metabolism. Newly synthesized triglyceride (site I) originates
from the liver as VLDL and is then hydrolyzed by an enzyme
system of lipoprotein lipase (LPL; site 2) situated in
extrahepatic tissues such as adipose tissue, muscle, and vascu-
lar endothelium. Under the influence of LPL, triglycerides are
removed progressively from VLDL, leaving behind smaller
remnants of intermediate density lipoprotein (IDL), and na-
scent HDL. Lipoprotein lipase requires a peptide, apolipopro-
tein-CII (apo-CIl), to be activated; this peptide is transported
by 1-IDL and transferred to VLDL during the catabolic process
(site 3). The lipoprotein lipase reaction also is stimulated by the
glycosaminoglycan, heparan sulfate [70]. Nascent HDL is cat-
alyzed to HDL by the enzyme lecithin-cholesterol acyl trans-
ferase or LCAT (site 4). Intermediate-density lipoprotein is
converted to LJJL in the liver and probably within the circula-
tion as well (site 5) and is then taken up by peripheral tissues
and by the liver (site 6). The uptake of IDL by the liver is a key
step in the lipoprotein synthetic pathway, because it has the
important role of suppressing de-novo synthesis of hepatic
lipids [701. High-density lipoprotein (site 3) is made by the liver
as well as during the LPL reaction; it shuttles apo-CIl to VLDL
and carries cholesterol to the liver for excretion. Defects at any
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site (I to 6) in this pathway can result in an accumulation of
lipoproteins in the circulation; in nephrotic syndrome, defects
have been described at almost every location, but the primary
cause of hyperlipoproteinemia appears to be an increased rate
of hepatic synthesis of lipoproteins [69, 71—73]; a reduction in
catabolic removal plays an additional role [72, 74].
Hepatic synthesis of lipoproteins (site 1) is markedly in-
creased in humans and in animal models of the disease. Both
the lipid and protein moieties of the lipoprotein fractions are
affected, and these alterations probably form the main basis for
hyperlipidemia [69, 7 1—73]. Apart from this defect, some studies
also have shown a decrease in the rate of removal of the
lipoproteins from the circulation [72, 74]. In theory, defects in
the enzymes LPL or LCAT, abnormal HDL physiology, or
defective removal of LDL all could prevent or reduce the
subsequent removal of VLDL. Although initial measurements
of LPL activity (site 2) in nephrotic syndrome produced normal
results [751, later studies have shown LPL activity to be
reduced by 30% to 60% of normal, a defect that clearly would
retard VL])L removal [76]. The reasons for reduced LPL
activity are not known. Some believe it is a consequence of
hypoalbuminemia [73, 74]. Because free fatty acids released by
the action of LPL on VLDL normally are rapidly bound to
albumin, hypoalbuminemia would permit a greater accumula-
tion of free fatty acids in adipose tissue, a state known to retard
LPL activity. Others believe that LPL is inhibited by a circu-
lating plasma factor, or that its action is retarded by a deficiency
of apo-CII or other activator peptides (such as heparan sulfate)
that arises from changes in synthesis rates and urine losses [70,
76].
Studies in nephrotic syndrome also have shown a reduction
in the activity of the enzyme LCAT (site 4), an abnormality that
would reduce HDL production [77]. This LCAT deficiency
would limit the availability of co-peptides for enzyme action
and would reduce the amount of cholesterol that could be
removed from peripheral tissue, such as vascular endothelium.
The reasons for low LCAT levels in nephrotic syndrome are
unclear. Such reductions simply might be due to urine loss;
alternatively, in the presence of hypoalbuminemia, lysolecithin
(produced during the process of cholesterol esterification by
LCAT) cannot be removed at an optimally steady rate, and this
might cause the LCAT reaction to slow down [77].
Conflicting data exist regarding HDL levels in humans and
animals with nephrotic syndrome, and several recent studies
have failed to resolve the issue. Some have shown clearly
reduced levels [65, 66, 77]; others report HDL levels to be
normal or elevated [12, 68, 76, 78, 79]. Because HDL has
approximately the same molecular dimensions as does albumin,
one would expect HDL to be lost in the urine in nephrotic
syndrome; indeed, studies have confirmed its presence there
[80]. The amount lost via this route varies, however. In one
study, patients with minimal-change disease showed low urine
and high blood levels of HDL, whereas in patients with ne-
phrotic syndrome from other causes, considerable amounts of
HDL were found in the urine, and blood levels were reduced
[781. Indeed, in support of this suggestion, the patient we are
discussing today had low levels of HDL in the plasma in
association with membranous nephropathy as a cause of ne-
phrotic syndrome. A recent study in children confirmed in-
creased HDL levels in patients with minimal-change disease but
reduced levels in children with nephrotic syndrome from other
glomerular lesions [79]. It is also possible that increased liver
synthesis of HDL might compensate better for urine losses in
some instances than in others.
Consequences of hyperlipidemia
The most important consequence of hyperlipidemia is its
potential for inducing cardiovascular disease. Even though
patients with nephrotic syndrome have several risk factors,
including hypertension, hypercoagulability, and hyperlip-
idemia, the incidence of ischemic heart disease in these patients
is uncertain—in part because such patients form a heteroge-
neous group. Two factors seem important in determining
whether a particular nephrotic patient is at high risk of devel-
oping vascular disease. The first is the duration and persistence
of hyperlipidemia. In this regard, most nephrotic patients found
to have heart disease have had persistent proteinuria and
nephrotic syndrome for years rather than months [81]. Coro-
nary disease appears to be unusual, for example, in patients
with minimal-change disease, in which the lipid abnormality
ordinarily is short-lived and intermittent. On the other hand, a
recent study of childhood nephrotic syndrome found in a
significant number of cases that cholesterol, triglycerides, and
lipoproteins had remained increased even during remission and
even when remission had been prolonged [79]. Thus, at least
some nephrotic children may have prolonged hyperlipidemia,
even after clinical remission, and be at increased risk of
developing premature atherosclerosis.
The second factor relates to the presence of increased levels
of the possibly protective lipoprotein HDL in these patients.
Recent studies of the relationship between serum cholesterol
levels and morbidity or mortality from cardiovascular disease
suggest that the critical factor might be not the absolute level of
total cholesterol, but either the level of associated HDL cho-
lesterol or the ratio of HDL cholesterol to total and LDL
cholesterol levels [82]. In patients with nephrotic syndrome, if
HDL cholesterol were elevated, the risk of vascular disease
might not be increased. As I mentioned, HDL levels are high in
some patients and low in others; these observations suggest that
the cardiovascular risk probably also varies. Studies of HDL
subfractions are also important in assessing cardiovascular risk.
Observations suggest that the HDL2 rather than the HDL3
fraction is most closely associated with an increased cardiovas-
cular risk [12]. In one recent report of patients with nephrotic
syndrome, although total cholesterol and total HDL levels were
normal, HDL2 was decreased in males and was trending down
in females [121. In the largest study of patients with nephrotic
syndrome, HDL cholesterol levels were normal or high, and the
incidence of cardiovascular disease was not increased [83]. In
contrast, other, smaller studies have reported a higher risk for
cardiovascular disease [811. On balance, it seems likely that
some, but not all, nephrotic patients are at risk for ischemic
heart disease. Patients with nephrotic syndrome who have high
levels of HDL cholesterol and normal HOL-to-total cholesterol
ratios, whatever their underlying disease, are likely to be at
lower risk. On the other hand, if HDL levels are reduced (or
perhaps even normal in the presence of increased total choles-
terol), and particularly if the nephrotic state persists over some
years, the risk of developing cardiovascular disease is probably
increased. Current data suggest that the risk of vascular disease
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is not markedly increased in patients with nephrotic syndrome,
and routine manipulation of plasma lipids does not seem justi-
fied in all cases; however, it might be justified in patients with
persistent, severe nephrotic syndrome. Certainly, lipid-lowe-
ring agents can lower cholesterol, LDL, and triglycerides and
produce either no change or an increase in HDL levels in
patients with nephrotic syndrome [84, 85].
The hypothesis recently has been advanced that hyperlipid-
emia in nephrotic syndrome has another consequence, namely
glomerular injury [86—89]. It originally was proposed that fil-
tered lipoproteins might accumulate in the mesangium and
promote sclerosis [86]. Subsequently, free and esterifled cho-
lesterol was found in the glomeruli of nephrotic rats, and a close
correlation was noted between plasma cholesterol levels and
the number of sclerosing glomerular lesions [87]. The authors
called this lesion "atherosclerosis of the glomerular mesan-
gium" [87]. In 2 preliminary reports, the incidence of renal
failure and of focal glomerular sclerosis in the rat remnant
kidney model was markedly reduced by treatment with lipid-
lowering agents [88, 89]. This exciting new work suggests that
lipid accumulation in the glonierular mesangium might play an
important role in progressive glomerular damage and renal
failure; therapeutic normalization of plasma lipids might even
prove to be of value in slowing the rate of renal failure, but
much more work is needed to establish this point. It certainly
seems as if the relationship is not a simple one, however. In a
recent preliminary report, comparable degrees of hyper-
cholesterolemia produced significant glomeruloscierosis in the
Wistar but not in the PVG strain of rat [90], It seems likely that
hyperlipidemia alone is not responsible for the glomerular
damage, but that unless both hyperlipidemia and mesangial cell
dysfunction are present, as in the Wistar rat, glomerulosclerosis
will not result.
Immune status
Patients with nephrotic syndrome have low serum levels of
gamma globulin and IgG (often affecting the various IgG sub-
classes differently). Three mechanisms seem responsible: loss
of IgG in the urine, an increase in catabolic rate, and a reduced
rate of synthesis [3, 91, 92]. Immunoglobulin synthesis by
pokeweed mitogen-stimulated lymphocytes, defective during
relapse, returns to normal in remission [91]. Antibody response
to administered antigens is reduced [931. Also, IgA levels are
decreased in nephrotic syndrome, whereas 1gM usually is
increased, particularly in patients with minimal-change disease
and normal renal function [94]. Indeed, 1gM can remain ele-
vated for several years after remission has occurred. The
reason and significance of this finding is unknown. Levels of
IgE also are elevated in cases of minimal-change disease,
perhaps because an atopic tendency exists in these patients
[95].
Important defects in cell-mediated immunity also occur in
nephrotic syndrome [96, 97]. The total number of circulating
T-lymphocytes is reduced, T-cell subsets often are abnormal,
the blastogenic response by lymphocytes to the mitogens con-
canavalin A and phytohemagglutinin is reduced, and delayed
cutaneous hypersensitivity reactions frequently are abnormal.
These abnormalities generally revert to normal following remis-
sion of nephrotie syndrome, although less frequently if cyclo-
phosphamide has been given [97]. One study in children with
nephrotic syndrome demonstrated reduced .splenic function,
which returned to normal with remission and correlated closely
with infectious episodes [98].
Several mechanisms have been suggested to account for
these abnormalities of cellular immunity. Because normal lym-
phocytes are inhibited in their response to mitogenic stimulants
by plasma from nephrotic patients, the appearance of a new, or
loss of a physiologic circulating serum factor that affects T-cell
function has been postulated [96]. One study in children sug-
gested a close correlation between abnormal lymphocyte pro-
liferative responses and transferrin deficiency; the markedly
abnormal in-vitro lymphocyte transformation response to con-
canavalin A was corrected when transferrin was added [99].
Transferrin, the iron-binding protein, is necessary for in-vitro
growth of lymphocytes and in the proliferation of T-cell lines
[991. Other studies have suggested that deficiency of zinc might
play a role [100]. Zinc is important for the normal biologic
activity of thymic hormones [lOll; thus zinc deficiency, com-
mon in nephrotic patients, might impair normal immune re-
sponses. Others have suggested that increased production of
prostacyclin in nephrotic syndrome is the cause of the inade-
quate response of lymphocytes to mitogens [102] because the
defect was correctable with indorriethacin [103]. Finally, one
group found that although plasma from patients with nephrotic
syndrome inhibited the normal lymphoproliferative response to
mitogens, removal of the lipoprotein fraction completely nor-
malized this response. This observation suggests that hyperlip-
idemia is responsible for the abnormal cellular immunity in
nephrotic syndrome [104].
Complement levels are not reduced by the nephrotic syn-
drome per se, and may even be increased [105]. One study
reported a potentially important complement abnormality in
nephrotic syndrome, namely, significantly depressed levels of
serum factor B [106]. Factor B, or C3 proactivator, a compo-
nent of the alternate complement pathway, was reduced during
relapse, probably because of urine losses, and increased
towards normal when remission occurred [1061. Of particular
importance was the observation that during relapse the serum
of these patients had a reduced capacity to opsonize F. coil and
that this capacity could be restored to normal by the addition of
pure factor B to nephrotic serum, These defects in immune
responses probably explain nephrotic patients' high suscepti-
bility to infection.
Increased susceptibility to infection
Before the era of antibiotics and steroids, infection was the
most common cause of death in patients with nephrotic syn-
drome. The organisms most frequently encountered were
Streptococcus pneumoniae and Escherichia coil; infections of
the lungs (as in the patient being discussed today) and perito-
neum were the most common sites. Many factors, as 1 already
have outlined, are responsible for this high susceptibility to
infection, including insufficient immunoglobulin production,
inadequate antibody responses, inadequate opsonization, and
defective cell-mediated immunity. Immunosuppressive therapy
can contribute of course. Peritonitis is a particular problem. In
one large review, approximately 6% of children with nephrotic
syndrome suffered one or more episodes [107]. It has been
suggested that low levels of complement and immunoglobulin in
the ascitic fluid, together with a generalized reduction in ascitic
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bactericidal activity, account for the tendency for peritonitis to
occur.
The incidence of fatal infection in nephrotic syndrome has
fallen considerably. This reduction is partly due to the avail-
ability of highly potent antibiotics, and partly-—at least in
children—to the high incidence of steroid-responsive, minimal-
change disease. However, a risk of serious infection always is
present in nephrotic syndrome, and aggressive antibiotic ther-
apy should be instituted at the first suspicion of an infection.
Prophylactic measures, such as pneumococcal vaccine, should
be applied in patients with nephrotic syndrome and severely
depressed immunoglobulins, particularly in young children, and
especially when early remission is not anticipated. Although the
initial antibody response to pneumococcal vaccine is favorable,
by one year 50% of patients have failed to maintain adequate
antibody concentrations against several pneumococcal capsular
types [108]. Despite this figure, it is currently recommended
that all nephrotic children over 2 years of age, and many adults
with severely depressed immunoglobulins, be vaccinated with
the 23-valent pneumococcal vaccine [1081.
Calcium and hone metabolism
Hypocalcemia, hypocalciuria, reduced intestinal absorption
of calcium, blunted calcemic response to parathyroid hormone
(PTH), and the presence of osteomalacia and/or hyperparathy-
roidism have been demonstrated in patients with nephrotic
syndrome [109, 110]. Although hypocalcemia initially was at-
tributed to hypoalbuminemia, studies of ionized calcium levels
in many patients show low levels [110—112]. Reduced blood
levels of vitamin D and its metabolites are found in many
nephrotic patients; a vitamin D-deficient state explains these
abnormalities in calcium metabolism [111, 113. 114]. Initial
studies in nephrotic syndrome revealed low blood levels of
25-hydroxyvitamin D (25-OH-D) [109—ill, 113]. The detection
of this vitamin D metabolite in the urine led some workers to
assume that the low blood level was due to its urinary excretion
with the vitamin D carrier protein [1131. Later, reduced levels
of 1,25 dihydroxyvitamin D [1 ,25(OH)2D] were found in some
studies [109, 110, 114], although not in all [I 15J. Since these
original observations, additional studies have examined the
status of calcium and vitamin D metabolism in nephrotic
syndrome, and its impact on the skeleton, but no consistent
pattern has emerged [112, 115, 116]. Although virtually all
studies agree that plasma levels of 25-OH-D are reduced in
nephrotic syndrome, and often 25,26-OH-D and 24,25-OH-D as
well, the data relating to l,25(OH)2D are controversial; some
authors have found levels to be low; others, as in today's
patient, report them to be normal; and some believe that they
are low predominantly in patients receiving glucocorticoids
[114, 1161. Some have argued that because the assay for
I ,25(OH)2D measures both free and bound vitamin, no conclu-
sions can be drawn about the significance of the findings
because only the free amount is physiologically important. In
one recent study of nephrotic patients, a free 1,25 index" was
significantly lower than control, even in patients with normal
renal function [117]. Even the data regarding blood levels of
ionized calcium and PTH conflict. Some authors report normal
levels of both despite low blood levels of vitamin D metabolites
and suggest that unbound (free) levels of vitamin D must be
normal [114, 116]. Yet others report the ionized calcium to be
Table 1. Bone histology in nephrotic syndromea
Osteoma-
(%)
Normal
(%)
Osteo-
malacia
(%)
lacia plus
resorption
(%)
Nephrotic syndrome with normal 76 17 7
renal function
Nephrotic syndrome with azotemia 35 25 40b
Azotemia without nephrotic 53 34 13
syndrome
a Data from Ref. 112.b p = < .05, group II versus Ill.
reduced and the PTH levels to be normal or increased [109, 110,
115, 118].
The impact of these abnormalities on the skeleton remains
unclear. A few children in the one- to two-year age group with
nephrotic syndrome have developed rickets, and they have
exhibited bone healing after receiving large doses of vitamin D
[119]. Evidence of bone disease or vitamin deficiency has been
found in children with nephrotic syndrome [115]. In this study,
although 1 ,25(OH)2D levels were normal, bone densitometry
showed values below 90% of normal in 6 of 9 children. In
another report, weakness and proximal myopathy occurred in
one child who had low levels of total calcium, ionized calcium,
25-OH-D, and l,25(OH)2D [1181. All biochemical abnormalities
were corrected, and the weakness and myopathy disappeared
with oral vitamin D therapy.
No clinical or radiologic evidence of bone disease has been
reported in adults with nephrotic syndrome. Histomorpho-
metric studies conflict: some find no bone disease [1161, and
others find evidence of osteomalacia and hyperparathyroidism
[110]. One important study examined bone histology and cal-
cium metabolism in two sets of patients with nephrotic syn-
drome—one with normal, the other with reduced renal func-
tion—and compared the findings with those from a group of
non-proteinuric azotemic patients with comparable levels of
renal functional impairment [112]. Table 1 summarizes the data
from the study. In patients with normal renal function, ionized
calcium was reduced in 5 of 9 patients and 25-OH-D levels were
low, but l,25(OH)2D and PTH levels were normal. Bone
histology, normal in 76% of the patients, showed osteomalacia
in 17% and bone resorption in 7%. However, when renal
function began to decline, 1,25(OH)2D levels fell, mineraliza-
tion was markedly decreased, and bone resorption became
abnormal in 40% of patients; this percentage was significantly
greater than the 13% incidence found in a group with compara-
ble degrees of renal failure in the absence of nephrotic syn-
drome [112]. Thus in the presence of nephrotic syndrome and
normal renal function, bone disease is not common, but when
renal function declines, severe osteodystrophy is likely to
result. Studies are needed to confirm this finding and to deter-
mine the dose, timing of administration, and preparation of
vitamin D that could prevent this complication. It is possible
that patients with nephrotic syndrome from a glomerular lesion
likely to produce progressive renal failure, as in the patient we
are discussing today [120], should have the biochemical abnor-
malities corrected. Certainly, vitamin D therapy can effectively
normalize blood levels. In one study, treatment with vitamin D3
for 4 to 52 weeks elevated 25-OH-D in 8 of 9 patients and raised
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Most common defects.
Table 2. Hemostatic factors in nephrotic syndrome
Reduced: II. IX, Xl. Xl!
Increased: Vii, X
Increased: V and Vtt1
Increased
Reduced: antithrombin lI1
Increased: alpha-2 macroglobulin
Reduced: plasminogen
Increased antiplasmins:
alpha-2 macroglobulin,
alpha-2 antiplasmin
Reduced antipiasmins:
alpha-I and alpha-2 antitrypsin
Thrombocytosis
Increased adhesiveness
tncreased aggregation'
I ,25(OH)2D in 5 of 9 patients, at least while renal function
remained normal [1211.
Abnormalities of coagulation
Thromboembolism is one of the most serious complications
of nephrotic syndrome. The most frequent site of thrombosis is
the renal vein, with a reported incidence (documented by
venography) varying from 2% to 62%, with an average of about
35%. Approximately 40% of these patients have pulmonary
emboli, although death from this cause is rare. Clinical evidence
of renal vein thrombosis is present in 4% to 8% of cases.
Noninvasive studies (ventilation/perfusion scans) reveal that
approximately 20% of adults with nephrotic syndrome have
evidence of pulmonary embolic disease, although no more than
one-half have clinical evidence of pulmonary emboli and/or
deep-vein thrombosis [122]. The magnitude of the problem is
now thought to be similar in children [123]. Thrombotic com-
plications also can involve major arteries such as the pulmo-
nary, axillary, renal, aortic, femoral, coronary, and mesenteric,
and the axillary and subclavian veins [124].
Profound changes occur in nephrotic syndrome in the pro-
teins concerned with initiating both coagulation and fibrinolysis
[122, 125]. This defect arises because of widespread alterations
in synthesis, turnover, and urine losses that affect many pro-
teins in nephrotic syndrome. The majority of patients with
nephrotic syndrome have a hypercoagulable state. Deficient
hemostasis is infrequent. The role of this hypercoagulable state
in the thromboembolic complications has not been established,
however, A causal relationship between the hypercoagulability
and the development of thrombosis has not been demonstrated
[122, 125].
Table 2 summarizes the numerous defects in hemostasis that
occur in nephrotic syndrome. Alterations in the concentrations
of almost every coagulation factor and clotting inhibitor as well
as defects in platelets and the fibrinolytic system can occur
[122, 125]. The situation is confusing and complicated; some
coagulation factors seem increased (V, VII, VIII, X, and
fibrinogen) and others decreased (11, IX, XI, XII); some clotting
inhibitors are increased (alpha-2 macroglobulin) and others
decreased (antithrombin Ill, alpha 1-antitrypsin); evidence of
increased (reduced alpha-i and alpha-2 antitrypsin) or reduced
(reduced plasminogen and increased alpha-2 macroglobulin and
alpha-2 antiplasmin) activity of the fibrinolytic system is pres-
ent. Finally, several studies have demonstrated marked platelet
hyperactivity [34, 122, 125]. The platelet count is often in-
creased, and platelet adhesiveness and aggregation (both spon-
taneously and in response to stimulants) is much exaggerated.
Some believe that hypoalbuminemia plays a role in the platelet
hyperactivity [341; others blame hyperlipoproteinemia [1261 or
complex alterations in other plasma proteins [1271. Beta-
thromboglobulin, a protein released by platelets on aggregation,
often is elevated in the serum of patients with nephrotic
syndrome [128],
The major coagulation abnormalities in the nephrotic state
include increased levels of factors V, VIII, and plasma fibrin-
ogen; a decreased level of antithrombin III; thrombocytosis;
and an increased level of platelet aggregation. Although it is not
yet possible to attribute the clotting tendency in nephrotic
syndrome to hypercoagulability, certain of the defects do seem
to be better predictors of thromboembolism than others. The
following derangements may be useful clinically: a low level of
antithrombin III (below 75%), which correlates closely with a
clotting tendency [129]; an increased alpha-2 antiplasmin,
which may be the most reliable marker of renal-vein thrombosis
[1301; and an increased level of beta-thromboglobulin, which
may be a sign of platelet aggregation [128].
Many studies lack the longitudinal approach needed to estab-
lish the particular defects that best identify patients at higher
risk of thromboembolism. When this information becomes
available, studies will be necessary to assess the value of
prophylactic anticoagulation in these high-risk patients. In the
meantime, anticoagulation with warfarin seems indicated, for as
long as the nephrotic syndrome persists, in all patients who
develop thromboembolic disease and in those at high risk
because of unavoidable immobilization (for example, patients
with pelvic or limb fractures). Although prophylactic anticoag-
ulation for all patients with nephrotic syndrome cannot be
supported, some believe it is reasonable to consider such
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therapy in patients whose plasma albumin is below 2 g/dl, and
perhaps in those with membranous nephropathy [122, 123].
Simple prophylactic measures of encouraging leg exercises,
avoiding volume depletion, avoiding immobilization, and avoid-
ing femoral artery or vein punctures should always be applied.
Miscellaneous
Several other complications of a metabolic nature can occur
in nephrotic syndrome [I]. Low levels of the metals copper,
iron, and zinc occur in nephrotic patients [131], as do their
carrier proteins ceruloplasmin [64] and transferrin [132, 133],
probably from loss in the urine. Today's patient had low zinc
and transferrin levels. The significance of these low levels is
unknown; iron deficiency is rare [132, 133] but, as I discussed
before, transferrin and/or zinc deficiency can produce defective
cellular immunity [99, 100]. Urinary loss of thyroxine-binding
globulin alters blood levels of thyroid hormones and may
confuse interpretation of thyroid function tests, although the
patients remain euthyroid [I, 134]. Protein malnutrition can
arise from combinations of poor intake, massive urinary losses,
and increased catabolism; such protein deficits can be devas-
tating in growing children [119]. Finally, dysfunction of renal
tubular cells, presumably related to resorption of filtered pro-
tein, can lead to features of proximal tubular dysfunction and
can manifest with glycosuria, aminoaciduria, phosphate and
potassium wasting, and hyperchloremic acidosis [1].
Questions and answers
DR. NlcoLAos F. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts):
Shouldn't we be able to advance our understanding of the
pathophysiology of edema formation in nephrotic syndrome by
comparing the findings of studies such as those you described in
nephrotic syndrome with similar studies carried out in other
hypoalbuminemic states such as protein-losing enteropathy or
malnutrition? Have such studies been done?
DR. BERNARD: I am not aware of any studies in hypoalbu-
minemic states, other than nephrotic syndrome, that have
simultaneously examined plasma volume, plasma oncotic pres-
sure, and interstitial oncotic pressure, together with urinary
sodium excretion rates. Such studies certainly would be inter-
esting. However, at least one piece of indirect evidence relating
to non-nephrotic hypoalbuminemnia indicates that a renal sodi-
um-retentive defect unrelated to hypoalbuminemia is critical in
edema formation in nephrotic syndrome: the lack of edema in
patients with analbuminemia [37]. Such patients have markedly
reduced plasma oncotic pressures, as low as 10 to 14 mm Hg,
but no clinical water or electrolyte disturbance [37]. Further-
more, even in nephrotic syndrome, hypoalbuminemia is not
always associated with edema. We all have seen patients with
no edema in the presence of severe hypoalbuminemia, and
experimentally severe proteinuria and hypoalbuminemia are
not inevitably associated with edema [36]. These facts strongly
argue that a renal defect in sodium excretion unrelated to
hypoalbuminemia must be present if the extracellular space is
to expand and edema is to occur.
DR. JEROME P. KASSIRER (Associate Physician-in-Chief, De-
partment of Medicine, New England Medical Center): When I
last reviewed the mechanisms of hypoalbuminemia in nephrotic
syndrome, I was struck by the concept of tubular reabsorption
and degradation of protein as an interesting way of explaining
the discrepancy between moderate protein losses and remark-
able reductions in serum albumin. I have a problem with that
now. If it is true in nephrotic syndrome that plasma proteins are
filtered, reabsorbed by the tubules, and then degraded, one
would predict that hypoalbuminemia occasionally might occur
before proteinuria appeared in patients who develop recurrent
nephrotic syndrome. In fact, these two events, at least from
clinical observations, tend to be simultaneous. One also might
predict, based on these principles, that we might see an
occasional patient with glomerular disease who has hypoalbu-
minemia with only minimal proteinuria. Yet we do not recog-
nize such a phenomenon. Would you comment on this apparent
discrepancy?
DR. BERNARD: The easiest way for me to answer your
question is to emphasize that the pathophysiology of hypoalbu-
minemia in nephrotic syndrome is undoubtedly multifactorial.
Clearly, the plasma albumin concentration can vary from pa-
tient to patient, and from time to time in a single patient,
depending on the net balance between the rate of hepatic
synthesis of albumin, dietary intake of protein, urine losses of
albumin, and the rates of catabolism of albumin by renal and
extrarenal sources. Diet in fact might be a critical factor; as I
mentioned earlier, some British nephrologists claim that with
aggressive protein and calorie supplementation, hypoprotein-
emia is unusual, even in the presence of heavy proteinuria [12].
Conversely, in the presence of an inadequate diet, it should be
possible to develop hypoalbuminemia with only minimal pro-
teinuria, if rates of hepatic synthesis are low and renal catabolic
rates are high. As far as the first part of your question is
concerned, I don't believe we know for sure exactly what
happens to plasma albumin concentration just before the onset
of a relapse in recurrent nephrotic syndrome. That would be a
difficult study to do because the timing of a relapse is, of course,
unpredictable. Certainly by the time most patients have devel-
oped heavy proteinuria they also have hypoalbuminemia. But I
agree that at least theoretically it might be possible for
hypoalbuminemia to occur before proteinuria.
DR. KA5sIRER: But you haven't fully addressed my question
about renal degradation of filtered proteins. When the glomeruli
begin to leak, presumably the tubules have the "first crack" at
the filtered protein, and if that is the case, then those proteins
would be lost to the circulation. In principle, hypoalbuminemia
might develop in some instances even without overt protein-
uria.
DR. BERNARD: We should consider two additional factors.
First, it is presumed that at least some of the albumin metabo-
lized by the renal tubules is converted into its constituent amino
acids, which are then returned to the circulation to rejoin the
body pool of protein [135]. So not all is lost. Presumably the
proportion of filtered and reabsorbed protein that is returned to
the circulation and that which is locally catabolized and perma-
nently lost from the body pool vary under different circum-
stances. For example, perhaps when the filtered load of albumin
is not very high, all reabsorbed protein is returned to the
circulation; it is possible that local catabolism only becomes
important in the presence of high rates of proteinuria. In that
situation, hypoalbuminemia would not occur until proteinuria
were substantial. Considerable evidence indicates that renal
albumin catabolic rates increase as proteinuria increases [1, 3,
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5, 14]. This finding raises the second point relating to the
possible existence of a dual transport system for tubular albu-
min uptake [18]. Perhaps the low-capacity system that is
responsible for albumin reabsorption at low rates of filtration
accounts for the return of absorbed protein to the body,
whereas the high-capacity, low-affinity system, which "turns
on" when the filtered load increases, permits increased tubular
reabsorption and local catabolism. I realize these are not totally
satisfactory answers, but I don't believe we have any better
insight at present.
DR. RONALD D. PERRONE (Division of Nephrology, New
England Medical Center): Measurement of the blood volume is
extremely sensitive to the marker used. The validity of a marker
for blood volume depends on its being confined to the intravas-
cular space. Is the validity of this method established for
hypoalbuminernic nephrotic patients?
DR. BERNARD: The transcapillary escape rate (TER) of
injected albumin has been studied in patients with nephrotic
syndrome and has been compared with that in normals [136].
The normal TER is 5% to 8% per hour, whereas in patients with
nephrotic syndrome the TER is elevated to 9.5 2.5% [136].
Using radiolabeled albumin, the overestimation of plasma vol-
ume that would result from this change would account for less
than 2% if a single post-injection sample only were used; the
percentage would be lower if several timed blood samples were
taken [40, 1361.
DR. PERRONE: In studies which show that attempts at in-
creasing blood volume in nephrotic patients were unsuccessful
in increasing interstitial volume, what method was used to
increase the blood volume? If crystalloid was used, it would
have been expected to leave the circulation.
DR. BERNARD: The studies I cited were those in which blood
volumes and extracellular fluid and interstitial volumes were
compared among edematous patients with nephrotic syndrome
in relapse and two other groups of patients, normal healthy
subjects volume-expanded to an almost comparable degree by
markedly increased sodium intake [52] and patients with
chronic renal failure who were spontaneously overhydrated by
a similar amount [42]. At comparable degrees of extracellular-
fluid volume expansion, blood volume, although normal or
increased, was considerably lower in nephrotic subjects than in
the other two groups. So, because of hypoalbuminemia, the
blood volume is not elevated in overhydrated nephrotic syn-
drome patients, whereas it is elevated in normoproteinemic
patients comparably expanded. This finding is viewed by some
as an important homeostatic mechanism protecting against
hypertension in nephrotic patients, and it might explain the
discrepancy between the common presence of hypertension in
non-nephrotic azotemic patients and the much less common
incidence of hypertension in nephrotic patients [42].
DR. MICHAEL P. MADAIO (Division of Nephrology, New
England Medical Center): Would you comment on treatment of
a patient, like the one presented in this Forum, whose protein-
uria has not responded to steroid therapy? Specifically, would
you attempt to reduce the protein excretion by alternative
pharmacologic measures?
DR. BERNARD: If a patient with nephrotic syndrome fails to
enter remission after having taken steroids and/or immunosup-
pressive agents, further attempts at eliminating proteinuria
probably are indicated only if a major metabolic complication
exists that cannot be treated in another way. The most obvious
reason for trying to eliminate proteinuria is to control intracta-
ble edema that is resistant to treatment with diuretics and salt
restriction; other possible reasons can include thromboembol-
ism, severe hyperhipidemia, severe protein malnutrition, and
life-threatening infections. Two main therapeutic approaches
exist: nonsteroidal antiinflammatory drugs and angiotensin-
converting-enzyme inhibitors. Indomethacin and other nonste-
roidal antiinflammatory drugs decrease proteinuria by 60% to
70%, especially if the patient is salt depleted and is taking
diuretics [27, 281. Glomerular filtration rate declines by a
smaller percentage. Withdrawal of the drug I to 3 years after
administration is followed by a return of proteinuria to pretreat-
ment levels in most cases [27]. This effect has been noted in
experimental studies as well [137]. The mechanism for the
resumed proteinuria might have to do with the drug's effect on
renal prostaglandin production [28, 137]. Experimentally, the
fall in protein excretion is accompanied by a reduction in the
amount of filtrate formed through the "shunt" pathway of the
glomerular capillary wall [1381. We should remember that
although the decline in GFR induced by the nonsteroidal
antiinflammatory drugs usually is reversible, that is not always
the case [29]. So considerable caution and close monitoring are
needed when these agents are used. In the patient we are
discussing, because of his severe edema, a very low plasma
albumin concentration, significant abnormalities of serum lip-
ids, and a lack of response to steroids, we did elect to begin
treatment with indomethacin, 75 mg daily. When the patient
was last seen, proteinuria and renal function were unchanged,
so the dose has been increased.
More recently, angiotensin-converting-enzyme inhibition has
been shown to reduce proteinuria in patients with a variety of
glomerular diseases and renal insufficiency [139]. I'm not aware
of any studies that have examined this effect systematically in
patients with nephrotic syndrome with normal renal function or
only moderate renal insufficiency. It seems reasonable to me,
however, to try these agents in patients with severe nephrotic
syndrome and serious complications in whom elimination of
proteinuria has not occurred with nonsteroidal antiinflamma-
tory drugs.
DR. VINCENT J. CANZANELLO (Division of Nephrology, New
England Medical Center): With respect to this particular pa-
tient, I notice renal venography was performed initially. Do you
believe that routine investigation of the renal veins is worth-
while in all patients with membranous nephropathy?
DR. BERNARD: Those studies had been done prior to the
patient coming to our hospital. The answer to your question is
no, I don't think routine radiologic investigation of the renal
veins is appropriate. Venography does seem indicated, how-
ever, in patients with nephrotic syndrome who present with
acute flank pain, macroscopic hematuria, unexplained rapid
deterioration in renal function, pleuritic chest pain, or other
evidence of pulmonary embolism. It has been suggested that
because of the high incidence of renal-vein thrombosis in
membranous nephropathy, all patients with that glomerular
lesion should routinely undergo venography, but there's no
consensus on this point [122].
DR. KASSIRER: You correctly described the prevalence of
renal vein thrombosis as reported in the literature as between
2% and 60%. If it is 2%, then I do not worry about doing routine
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renal venography. But if it is truly 60%, then your recommen-
dation doesn't make sense. In fact, if it is 60%, then in principle,
we should be performing renal venography in everyone who
presents with nephrotic syndrome. What is your opinion of the
reports of a high frequency of renal-vein thrombosis in patients
with nephrotic syndrome?
DR. BERNARD: I do not know the answer, The problem, of
course, is that renal-vein thrombosis is a very difficult diagnosis
to make. There are no reliable noninvasive methods for diag-
nosing renal-vein thrombosis, although CT scanning might have
some promise [140]. Even venography requires special skill in
conducting the test and interpreting the results; small venular
thrombi can be missed unless a venous-phase arteriogram is
done at the same time; on the other hand, venograms can show
apparent filling defects that are not thrombi. So perhaps tech-
nical factors or misinterpretations of the findings account for
the differences in reported incidence.
DR. KASSIRER: My view is that the frequency of renal-vein
thrombosis at any given moment in the life of the nephrotic
patient is not nearly as high as the highest figures. As you
pointed out, many of these reports of renal-vein thrombosis
have been misinterpreted because of the high blood flow in the
renal veins.
DR. CANZANELLO: How aggressively do you search for
malignancy in adults with newly discovered membranous
nephropathy?
DR. BERNARD: Until recently, it was believed that an under-
lying malignant process, usually a carcinoma, is present in 6%
to 10% of patients with membranous nephropathy: in one large
review, of all the instances of neoplasm in patients with
nephrotic syndrome, the renal lesion was membranous nephrop-
athy in 34% of cases; if carcinomas only were considered, this
figure was 69% [1411. On the other hand, recent studies have
questioned the validity of these findings because, in most cases,
control figures for the incidence of malignancy in a comparable
general population without nephrotic syndrome had not been
considered. These recent studies conclude that in fact no
convincing proof exists of increased malignancy in patients with
nephrotic syndrome [120, 142]. 1 believe it is appropriate to
perform routine cancer screening in all patients with nephrotic
syndrome. These tests, such as looking for blood in the stool
and obtaining a chest x-ray, should be based on the patient's
age and medical history. Procedures beyond these are not
justified by the data now available. The need for a full workup
for malignancy in all adult patients with membranous nephrop-
athy probably was overstated.
Da. MADrAS: I suspect that the risk of an associated malig-
nancy is higher in older patients with membranous nephropathy
than in younger patients. Are there data on this issue?
DR. BERNARD: Yes, there are, but again the data conflict.
One study reported that the incidence of malignancy in older
patients with membranous nephropathy was greater than 22%
[143], but the lack of controls makes this information difficult to
interpret. Another study found I of 16 elderly patients with
membranous nephropathy to have an underlying malignancy,
and considered that incidence to be no greater than that
expected in the population at large [144].
DR. DAVID SALANT (Chief, Renal Section, Boston University
Medical Center, Boston): Is it known what happens to the renal
sodium-retentive defect in nephrotic syndrome if one reduces
proteinuria with nonsteroidal antiinflammatory agents or con-
verting-enzyme inhibitors without treating the primary disease?
DR. BERNARD: I believe nobody has addressed that question.
In the studies I referred to previously, in which nephrotic
proteinuria had been reduced or eliminated by the use of these
agents, no statement was made about the effects on sodium
retention [27, 28, 137, 139]. In one of these studies, the authors
did comment that as proteinuria was reduced with indometh-
acm, plasma albumin concentration rose, but no data were
presented about sodium balance [27]. In one short-term study,
captopril was administered to 8 patients with nephrotic syn-
drome in relapse, and sodium excretion was measured [145].
Four days later, the patients were still markedly sodium avid
and gaining weight; however, no information was given about
changes in urinary protein excretion.
DR. MARK SISKIND (Renal Fellow, Boston University Medi-
cal Center, Boston): What happens to the blood volume in
patients with nephrotic syndrome when they are standing? Is it
possible that patients become hypovolemic in the upright posi-
tion and that posture then becomes an important stimulus to the
kidney to retain sodium?
DR. BERNARD: That question has been raised by some as a
potential flaw in the blood-volume studies reported to date.
Whereas most recent studies have shown blood and plasma
volumes to be normal in these patients, the measurements
generally have been done while the patient was in the recum-
bent position. In fact, when plasma volume is examined after
the patient has been standing, patients with nephrotic syndrome
do have a greater-than-normal reduction [146]. After 20 minutes
of upright posture, plasma volume in normal persons falls by
about 7% to 10%, and in patients with nephrotic syndrome by
15% to 18% [146, 1471. A recent study assessed whether this
"upright hypovolemia" was physiologically important in terms
of producing a renal sodium-retaining effect; heart rate, renin
and norepinephrine levels, and postural changes in blood pres-
sure were compared in nephrotic patients and controls. Blood
volume fell more in nephrotic patients, but no important differ-
ences in heart rate or blood pressure were apparent. On the
whole, changes in plasma renin and norepinephrine also did not
differ between the two groups. A small subset of patients was
identified who had an excessive increase in heart rate and
elevation of plasma renin on standing, although blood pressure
changes were the same as those for the entire group. Only one
patient, who had amyloid disease, developed postural hypoten-
sion. The authors concluded that, taken together, there was no
convincing evidence that the exaggerated hypovolemia in
standing nephrotics was exerting any significant circulatory
effects in the majority of patients and thus could not be
considered a signal for renal sodium retention.
DR. MADAm: What is the pathogenesis of acute, reversible
renal failure that occurs with nephrotic syndrome? What is your
therapeutic approach to these patients?
DR. BERNARD: lam not aware of any new information on this
point. A large number of causes of acute renal failure exist in
idiopathic nephrotic syndrome, including tubular necrosis and
allergic interstitial nephritis [148]. The most interesting type of
reversible acute renal failure in these patients is that which
occurs in association with unimpressive glomerular, tubular, or
interstitial changes on renal biopsy [25, 26, 1481. The causes of
this entity are unknown. A variety of suggestions have been put
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forward to explain it, including an increase in renal vascular
resistance, a decrease in glomerular capillary permeability, and
renal interstitial edema [25, 26, 1481. Many patients with
minimal-change disease who present with acute renal failure
have anasarca and massive proteinuria as well as oliguria [25,
261. Biopsies reveal no or mild evidence of tubular necrosis, but
interstitial edema can be marked. Edema is everywhere; why
not in the kidney as well? Interstitial edema might compress the
renal tubules, produce intrarenal obstruction, and increase
hydrostatic pressure in proximal tubules and Rowman's space.
This distal obstruction could lead to a full in the net hydraulic
pressure, thus favoring filtration. In most of these patients, renal
failure reverses with aggressive diuretic therapy, whether or not
remission of protcinuria subsequently occurs; this finding sug-
gests that diuretics can reduce renal interstitial edema as well
[251. An alternate mechanism has been suggested l'or increasing
proximal tubule and Bowman's space hydraulic pressure,
which would have the same effect, namely, tubule blockage by
inspissatcd protein casts [148, 1491. I think acute renal failure at
onset of nephrotic syndrome is more common than realized,
particularly in older patients with anasarca. Many have ele-
vated serum crcatinine levels when first seen and, although this
finding was assumed to he due to hypovolemia, that possibility
no longer seems tenable. The best treatment is steroids with
aggressive diuretic therapy.
DR. ANDREW S. LEVEY (Division of Nephrologv, New En-
gland Medical Center): The sedimentation rate in this patient
was 80 mm/hr. Frequently, in our search for a systemic inflam-
matory disease in patients with nephrotic syndrome, we mea-
sure the sedimentation rate. How high should we expect it to he
simply from the hypoalbuminemia and alterations in the plasma
proteins'!
DR. BERNARD: I do not know. My hematology colleagues
assure me there is no definitive study to answer that question.
Apparently a sedimentation rate over 100 mm/hr is unlikely to
be due to nephrotic syndrome alone, and 50 mm/hr or less
seems a more usual figure. I don't know what to say about those
between 50 and 100 mm/hr.
DR. KASSIRER: In my experience, sedimentation rates as high
as 100 mm/hr or even greater are common in nephrotic syn-
drome of all causes. I doubt that an elevated value of this
magnitude favors an inliammatory cause.
DR. SAiANi: Would you comment on the stimulus for
liepatic lipoprotein synthesis in nephrotic syndrome? Is it a
response related purely to hypoalbuminemia?
DR. BERNARD: This is another area where current knowledge
is incomplete, Some have argued that the increased hepatic
lipoprotein production is simply a result of increased liver
protein synthesis in response to hyalhuminemia. In support
of this idea, a close inverse relationship exists between the
elevated blood lipids and the lowered plasma albumin concen-
tration: when a remission from nephrotie syndrome occurs, the
serum cholesterol falls as the serum albumin rises, and an
infusion of albumin to nephrotic rats or humans acutely elevates
the plasma albumin concentration and reduces the serum lipo-
protein and lipid levels, by as much as 30% to 60% in some
cases [I. 62, 65. 66]. The notion has been put forward that
because VLDL and albumin follow the same synthetic and
secretory routes in the liver, the lipoproteins are simply inno-
cent bystanders in the reaction whose prime aim is to increase
albumin production Ill. However, the explanation certainly is
not as simple as that. Patients with nephrotic syndrome can
develop marked hyperlipidemia in the presence of nearly nor-
mal plasma protein levels. Some studies have failed to show any
correlation between the increased lipids and the low plasma
albumin, and hyperlipoproleinemia is not a universal finding in
ncphrotic syndrome even when hypoalhuminemia is present
[1]. In fact, several other ideas have been advanced. One is that
the stimulus to the liver to increase lipoprotein production is
related to a reduction in plasma oncotic pressure or tonicity;
infusions of dextran into nephrotic patients or animals have a
lipid-lowering effect comparable to that of albumin infusion
[ISO]. Furthermore, a reduction in apolipoprotein-B mRNA is
noted in cultures of liver cells when albumin or dextran is added
to the medium [1511. Another idea is that the liver's increased
production of lipoprotein might he a response to decreased
plasma viscosity. In one recent study of experimental nephrotic
syndrome, the injection of macromolecules to increase plasma
viscosity delayed the development of hyperlipidemia and re-
duced the blood lipid levels [152]. The authors hypothesized
that the lipoproteins restore plasma viscosity in nephrotic
syndrome, although this argument has been disputed by others
[661. Others have suggested that the liver responds to abnor-
malities in mevalonate metabolism in nephrotic syndrome [153].
These workers have demonstrated that excretion and metabo-
lism of mevalonate by the nephrotic kidney is reduced, and that
this reduction results in increased delivery of this cholesterol
precursor to the liver. Finally, it has been proposed that there
might he defective hepatic uptake of IDL in nephrotic syn-
drome because of abnormalities in the IDL molecule itself or in
its receptor [70]. The effect of this alteration would be to
eliminate the important negative feedback on hepatic lipid
synthesis normally exerted by the uptake and metabolism of
IDL.
Reprint i'eqnests to Dr. I). Bernard. Renal Unit, Boston Lfnii'ersitv
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